11-14 June 2026
European Hematology Association (EHA) Congress 2026
Stockholmsmässan
Stockholm
Sweden
Presentations details:
Title: Updated Safety and Efficacy Results of a Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination with Azacitidine and Venetoclax in Newly Diagnosed AML
Abstract ID: EHA-4924
Presenter: Curtis Lachowiez, MD, Oregon Health & Science University, Portland, United States of America
Presentation Date and Time: Saturday, June 13, 2026, 6:45-7:45 pm CEST
Abstract ID: EHA-4924
Presenter: Curtis Lachowiez, MD, Oregon Health & Science University, Portland, United States of America
Presentation Date and Time: Saturday, June 13, 2026, 6:45-7:45 pm CEST
Title: Safety and Efficacy of Iadademstat Plus Gilteritinib in the FRIDA Expansion Cohort of FLT3‑Mutated Relapsed/Refractory Acute Myeloid Leukemia
Abstract ID: EHA-5879
Presenter: Amir Fathi, MD, Massachusetts General Hospital, Boston, United States of America
Presentation Date and Time: Friday, June 12, 2026, 6:45-7:45 pm CEST
Abstract ID: EHA-5879
Presenter: Amir Fathi, MD, Massachusetts General Hospital, Boston, United States of America
Presentation Date and Time: Friday, June 12, 2026, 6:45-7:45 pm CEST